Global Neurological Biomarkers Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026
- Published Date: 2021-01-17
- Report ID: 38709
- Pages: 105
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Neurological Biomarkers market in this environment.
In terms of revenue, this research report indicated that the global Neurological Biomarkers market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Neurological Biomarkers industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Bio-Rad Laboratories aims at producing XX Neurological Biomarkers in 2020, with XX % production to take place in global market, QIAGEN accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Neurological Biomarkers Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Neurological Biomarkers Market
Bio-Rad Laboratories
QIAGEN
Alseres Pharmaceuticals
Abbott
Thermo Fisher Scientific
Acumen Pharmaceuticals
Myriad RBM, Athena Diagnostics
AbaStar MDx
BANYAN BIOMARKERS
...
Major Type of Neurological Biomarkers Covered in Prudent Markets report:
Metabolomic
Genomic
Proteomic
Imaging
Others
Application Segments Covered in Prudent Markets Market
Multiple Sclerosis
Alzheimers Disease
Parkinsons Disease
Autism Spectrum Disorders
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Neurological Biomarkers Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Metabolomic -Product Introduction and Major Manufacturers
1.1.2 Genomic -Product Introduction and Major Manufacturers
1.1.3 Proteomic -Product Introduction and Major Manufacturers
1.1.4 Imaging -Product Introduction and Major Manufacturers
1.1.5 Others -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Neurological Biomarkers Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis
3.1 China Neurological Biomarkers Market
3.1.1 Top Companies leading Neurological Biomarkers Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Neurological Biomarkers Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)
3.2 EU Neurological Biomarkers Market
3.2.1 Top Companies leading Neurological Biomarkers Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Neurological Biomarkers Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)
3.3 USA Neurological Biomarkers Market
3.3.1 Top Companies leading Neurological Biomarkers Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Neurological Biomarkers Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)
3.4 Japan Neurological Biomarkers Market
3.4.1 Top Companies leading Neurological Biomarkers Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Neurological Biomarkers Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)
3.5 India Neurological Biomarkers Market
3.5.1 Top Companies leading Neurological Biomarkers Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Neurological Biomarkers Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)
3.6 Southeast Asia Neurological Biomarkers Market
3.6.1 Top Companies leading Neurological Biomarkers Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Neurological Biomarkers Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Neurological Biomarkers Market
3.7.1 Top Companies leading Neurological Biomarkers Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Neurological Biomarkers Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)
4.1 Neurological Biomarkers Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Neurological Biomarkers Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)
5.1 Global Neurological Biomarkers Sales and Growth Rate (2021-2026)
5.2 Global Neurological Biomarkers Sales Value and Growth Rate (2021-2026)
6 Neurological Biomarkers Competitive Analysis
6.1 Bio-Rad Laboratories
6.1.1 Bio-Rad Laboratories Company Profiles
6.1.2 Bio-Rad Laboratories Product Introduction
6.1.3 Bio-Rad Laboratories Neurological Biomarkers Production, Revenue (2015-2020)
6.1.4 SWOT Analysis
6.2 QIAGEN
6.2.1 QIAGEN Company Profiles
6.2.2 QIAGEN Product Introduction
6.2.3 QIAGEN Neurological Biomarkers Production, Revenue (2015-2020)
6.2.4 SWOT Analysis
6.3 Alseres Pharmaceuticals
6.3.1 Alseres Pharmaceuticals Company Profiles
6.3.2 Alseres Pharmaceuticals Product Introduction
6.3.3 Alseres Pharmaceuticals Neurological Biomarkers Production, Revenue (2015-2020)
6.3.4 SWOT Analysis
6.4 Abbott
6.4.1 Abbott Company Profiles
6.4.2 Abbott Product Introduction
6.4.3 Abbott Neurological Biomarkers Production, Revenue (2015-2020)
6.4.4 SWOT Analysis
6.5 Thermo Fisher Scientific
6.5.1 Thermo Fisher Scientific Company Profiles
6.5.2 Thermo Fisher Scientific Product Introduction
6.5.3 Thermo Fisher Scientific Neurological Biomarkers Production, Revenue (2015-2020)
6.5.4 SWOT Analysis
6.6 Acumen Pharmaceuticals
6.6.1 Acumen Pharmaceuticals Company Profiles
6.6.2 Acumen Pharmaceuticals Product Introduction
6.6.3 Acumen Pharmaceuticals Neurological Biomarkers Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 Myriad RBM, Athena Diagnostics
6.7.1 Myriad RBM, Athena Diagnostics Company Profiles
6.7.2 Myriad RBM, Athena Diagnostics Product Introduction
6.7.3 Myriad RBM, Athena Diagnostics Neurological Biomarkers Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 AbaStar MDx
6.8.1 AbaStar MDx Company Profiles
6.8.2 AbaStar MDx Product Introduction
6.8.3 AbaStar MDx Neurological Biomarkers Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
6.9 BANYAN BIOMARKERS
6.9.1 BANYAN BIOMARKERS Company Profiles
6.9.2 BANYAN BIOMARKERS Product Introduction
6.9.3 BANYAN BIOMARKERS Neurological Biomarkers Production, Revenue (2015-2020)
6.9.4 SWOT Analysis
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
